Skip to main content
. 2017 Feb 20;8(33):55550–55561. doi: 10.18632/oncotarget.15548

Figure 3. Conversion percentages for ERα, PR, AR and HER2 compared to adjuvant therapy history.

Figure 3

a. Conversion percentages for ERα, PR and AR of patients that did and did not receive adjuvant endocrine therapy. Data for the 1% and 10% thresholds for positivity are shown. b. Conversion percentages for ERα, PR and AR of patients that did and did not receive adjuvant chemotherapy. Data for the 1% and 10% thresholds for positivity are shown. c. Conversion percentages for HER2 of patients that did and did not receive adjuvant chemo- or trastuzumab therapy. Data for the for IHC only and IHC in combination with FISH are shown.